论文部分内容阅读
目的 探讨原位肝移植治疗乙型肝炎相关疾病的效果及Lamivudine在防治肝移植后乙肝复发中的作用。方法 10例患者接受了原位肝移植,其中9例男性乙肝患者,1例女性为肝癌患者,术前无乙肝感染。9例乙肝患者6例并有不同程度的肝性脑病,1例并肝肾综合征,1例并上消化道大出血。9例乙肝中7例服用Lamivudine预防术后乙肝复发。结果8例存活2-15月,2例死亡。存活的8例中7例为乙肝患者,仅1例术后6月出现HBsAg（+）,但全部均肝功能良好;另1例为肝癌患者,术后出现乙肝。死亡的2例中1例为术后乙肝复发暴发性肝功能衰竭所致,另1例死于术后多器官功能衰竭。结论 原位肝移植加Lamivudine是治疗乙肝的有效方法,Lamivudine在观察期内可预防乙肝移植后乙肝复发。
Objective To investigate the efficacy of orthotopic liver transplantation in the treatment of hepatitis B-related diseases and the role of Lamivudine in the prevention and treatment of hepatitis B recurrence after liver transplantation. Methods Ten patients underwent orthotopic liver transplantation. Among them, 9 were hepatitis B patients and 1 was female. There was no HBV infection before operation. 9 cases of hepatitis B patients in 6 cases and have varying degrees of hepatic encephalopathy, 1 case of hepatorenal syndrome, 1 case of upper gastrointestinal bleeding. Seven out of nine hepatitis B patients took Lamivudine to prevent postoperative hepatitis B recurrence. Results 8 cases survived from 2 to 15 months and 2 died. Of the 8 surviving patients, 7 were hepatitis B patients, and only 1 patient had HBsAg (+) after 6 months. However, all of them had good liver function. The other 1 patient was liver cancer and hepatitis B occurred after operation. One of the two deaths was due to recurrent hepatitis B after fulminant hepatic failure, and the other one died of postoperative multiple organ failure. Conclusion orthotopic liver transplantation with Lamivudine is an effective treatment for hepatitis B. Lamivudine can prevent hepatitis B recurrence after hepatitis B transplantation during the observation period.